Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 511

1.

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.

Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators.

Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12.

PMID:
28606915
2.

Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.

Taskinen MR, Söderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietiläinen KH, Räsänen S, Lundbom N, Björnson E, Eliasson B, Mancina RM, Romeo S, Alméras N, Pepa GD, Vetrani C, Prinster A, Annuzzi G, Rivellese A, Després JP, Borén J.

J Intern Med. 2017 May 26. doi: 10.1111/joim.12632. [Epub ahead of print]

PMID:
28548281
3.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL.

Eur Heart J. 2017 Apr 24. doi: 10.1093/eurheartj/ehx144. [Epub ahead of print]

PMID:
28444290
4.

Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men.

Matikainen N, Söderlund S, Björnson E, Bogl LH, Pietiläinen KH, Hakkarainen A, Lundbom N, Eliasson B, Räsänen SM, Rivellese A, Patti L, Prinster A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR.

Nutr Metab Cardiovasc Dis. 2017 Jun;27(6):534-542. doi: 10.1016/j.numecd.2017.03.003. Epub 2017 Mar 18.

PMID:
28428027
5.

Intestinal alkaline phosphatase at the crossroad of intestinal health and disease - a putative role in type 1 diabetes.

Lassenius MI, Fogarty CL, Blaut M, Haimila K, Riittinen L, Paju A, Kirveskari J, Järvelä J, Ahola AJ, Gordin D, Härma MA, Kumar A, Hamarneh SR, Hodin RA, Sorsa T, Tervahartiala T, Hörkkö S, Pussinen PJ, Forsblom C, Jauhiainen M, Taskinen MR, Groop PH, Lehto M; FinnDiane Study Group.

J Intern Med. 2017 Jun;281(6):586-600. doi: 10.1111/joim.12607. Epub 2017 Apr 10.

PMID:
28393441
6.

Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD.

Mardinoglu A, Bjornson E, Zhang C, Klevstig M, Söderlund S, Ståhlman M, Adiels M, Hakkarainen A, Lundbom N, Kilicarslan M, Hallström BM, Lundbom J, Vergès B, Barrett PH, Watts GF, Serlie MJ, Nielsen J, Uhlén M, Smith U, Marschall HU, Taskinen MR, Boren J.

Mol Syst Biol. 2017 Mar 2;13(3):916. doi: 10.15252/msb.20167422.

7.

[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL.

Kardiol Pol. 2016;74(11):1234-1318. doi: 10.5603/KP.2016.0157. Polish. No abstract available.

8.

Kinetics of plasma triglycerides in abdominal obesity.

Björnson E, Adiels M, Taskinen MR, Borén J.

Curr Opin Lipidol. 2017 Feb;28(1):11-18. doi: 10.1097/MOL.0000000000000375.

PMID:
27898581
9.

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Taskinen MR, Borén J.

Curr Atheroscler Rep. 2016 Oct;18(10):59. doi: 10.1007/s11883-016-0614-1. Review.

10.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors/Task Force Members:, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL.

Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1. No abstract available.

PMID:
27594540
11.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members; Additional Contributor.

Eur Heart J. 2016 Oct 14;37(39):2999-3058. Epub 2016 Aug 27. No abstract available.

PMID:
27567407
12.

The Contribution of GWAS Loci in Familial Dyslipidemias.

Ripatti P, Rämö JT, Söderlund S, Surakka I, Matikainen N, Pirinen M, Pajukanta P, Sarin AP, Service SK, Laurila PP, Ehnholm C, Salomaa V, Wilson RK, Palotie A, Freimer NB, Taskinen MR, Ripatti S.

PLoS Genet. 2016 May 26;12(5):e1006078. doi: 10.1371/journal.pgen.1006078. eCollection 2016 May.

13.

ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.

Vergès B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, Duvillard L, Söderlund S, Matikainen N, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Aho S, Simoneau-Robin I, Taskinen MR.

J Clin Endocrinol Metab. 2016 Apr;101(4):1398-406. doi: 10.1210/jc.2015-3740. Epub 2016 Feb 2.

PMID:
26835543
14.

USF1 deficiency activates brown adipose tissue and improves cardiometabolic health.

Laurila PP, Soronen J, Kooijman S, Forsström S, Boon MR, Surakka I, Kaiharju E, Coomans CP, Van Den Berg SA, Autio A, Sarin AP, Kettunen J, Tikkanen E, Manninen T, Metso J, Silvennoinen R, Merikanto K, Ruuth M, Perttilä J, Mäkelä A, Isomi A, Tuomainen AM, Tikka A, Ramadan UA, Seppälä I, Lehtimäki T, Eriksson J, Havulinna A, Jula A, Karhunen PJ, Salomaa V, Perola M, Ehnholm C, Lee-Rueckert M, Van Eck M, Roivainen A, Taskinen MR, Peltonen L, Mervaala E, Jalanko A, Hohtola E, Olkkonen VM, Ripatti S, Kovanen PT, Rensen PC, Suomalainen A, Jauhiainen M.

Sci Transl Med. 2016 Jan 27;8(323):323ra13. doi: 10.1126/scitranslmed.aad0015.

PMID:
26819196
15.

Biomarkers and prediction of myocardial triglyceride content in non-diabetic men.

Granér M, Gustavsson S, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, Lauerma K, Lundbom N, Borén J, Nieminen MS, Taskinen MR.

Nutr Metab Cardiovasc Dis. 2016 Feb;26(2):134-40. doi: 10.1016/j.numecd.2015.11.002. Epub 2015 Dec 12.

PMID:
26803593
16.

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.

Matikainen N, Björnson E, Söderlund S, Borén C, Eliasson B, Pietiläinen KH, Bogl LH, Hakkarainen A, Lundbom N, Rivellese A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR.

PLoS One. 2016 Jan 11;11(1):e0145890. doi: 10.1371/journal.pone.0145890. eCollection 2016.

17.

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans.

Adiels M, Mardinoglu A, Taskinen MR, Borén J.

Front Physiol. 2015 Nov 20;6:342. doi: 10.3389/fphys.2015.00342. eCollection 2015. Review.

18.

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models.

Berglund M, Adiels M, Taskinen MR, Borén J, Wennberg B.

PLoS One. 2015 Sep 30;10(9):e0138538. doi: 10.1371/journal.pone.0138538. eCollection 2015.

19.

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study.

Borén J, Watts GF, Adiels M, Söderlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Vergès B, Barrett PH, Taskinen MR.

Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2218-24. doi: 10.1161/ATVBAHA.115.305614. Epub 2015 Aug 27. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):e57.

20.

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Ong KL, Januszewski AS, O'Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA, Keech AC; FIELD study investigators.

Diabetologia. 2015 Sep;58(9):2035-44. doi: 10.1007/s00125-015-3652-2. Epub 2015 Jun 9.

PMID:
26055067

Supplemental Content

Loading ...
Support Center